Be Bio Terminates BE-101 Hemophilia B Program
Be Biopharma terminated the Phase 1/2 BeCoMe-9 study of BE-101, the first engineered B cell medicine tested clinically in hemophilia B.
Be Biopharma
Be Biopharma terminated the Phase 1/2 BeCoMe-9 study of BE-101, the first engineered B cell medicine tested clinically in hemophilia B.
